Overview
Choose your reading level:
In plain language
Hexarelin is a lab-made peptide of 6 amino acids that strongly triggers growth hormone release from the pituitary gland.
It acts on the ghrelin receptor and also on a second receptor found in the heart, which is why scientists have studied it in heart research. Its effect fades if it is used continuously for a long time. It is not FDA-approved for any use.
For students
Hexarelin (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, about 887 Da) is a GHRP-6 analogue in which D-Trp is replaced by 2-methyl-D-Trp, increasing potency and stability. It was studied clinically in Italy in the 1990s.
It activates GHS-R1a and is among the most potent GH secretagogues in people. It also binds CD36, a scavenger receptor expressed in heart and blood vessels, and has shown cardioprotective effects in animal models independent of GH.
For researchers and instructors
Human evidence. Acute studies show robust GH release with increases in prolactin and cortisol. Partial, reversible attenuation of the GH response occurs with prolonged treatment.
Cardiac research. Small human studies reported acute effects on left ventricular ejection fraction, but no clinical program followed.
Regulatory and sport. Not FDA-approved. Prohibited by WADA.
Molecular identity
- Amino acids
- 6
- Molecular weight
- ~887.0 Da
- Formula
- C₄₇H₅₈N₁₂O₆
- Sequence
- His–D-2-Me-Trp–Ala–Trp–D-Phe–Lys–NH₂
Origin and history
Hexarelin was developed in the early 1990s by Romano Deghenghi at the company Europeptides. It is GHRP-6 with one change: a methyl group on its tryptophan, which made it more potent.
In 2002 researchers found it also binds a heart receptor called CD36, separate from the growth hormone receptor, which started research into protective effects on the heart. It has never been approved.
Key people
- Romano DeghenghiPeptide chemist, Europeptides
Timeline
- 1994
Hexarelin described
- 2002
CD36 identified as a heart receptor for hexarelin
See every peptide on one history timeline.
Human evidence
Small human studies measured growth hormone responses; a weaker response with repeated use (desensitization) has been reported. No long-term clinical benefit is established.
Registration and enrollment are not proof of benefit; check study results directly.
Explore original publications and distinguish preclinical findings from controlled human evidence.
Safety and regulatory status
See every compound on the regulatory tracker.
Not FDA-approved for any use.
This profile is educational and does not provide treatment, dosing or sourcing guidance.
Sources
- PubMed literature search: Hexarelin
- PubChem compound search: Hexarelin
- PubMed: hexarelin CD36
- ClinicalTrials.gov search: Hexarelin
Hernandez Gener, E. (2026, November 7). Hexarelin: molecular data, research history and evidence. VALREXA Biosciences. https://valrexa.com/peptides/hexarelin.html
APA style · Last reviewed November 7, 2026 · Our editorial standardsLast reviewed November 7, 2026. Trial and regulatory status can change; confirm in the linked registries. This profile is educational and is not medical advice, a treatment recommendation, or dosing or sourcing guidance. Report an error · Corrections policy